000			05405nam a22003735i 4500
001			280446
003			MX-SnUAN
005			20170705134203.0
007			cr nn 008mamaa
008			150903s2007 xxu| o |||| 0|eng d
020			_a9780387709093 _99780387709093
024	7		_a10.1007/9780387709093 _2doi
035			_avtls000332083
039		9	_a201509030735 _bVLOAD _c201404122022 _dVLOAD _c201404091750 _dVLOAD _y201402041020 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRB155-155.8
100	1		_aBarranger, John A. _eautor _9305368
245	1	0	_aLysosomal Storage Disorders / _cby John A. Barranger, Mario A. Cabrera-Salazar.
264		1	_aBoston, MA : _bSpringer US, _c2007.
300			_brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
500			_aSpringer eBooks
505	0		_aFrom Lysosomes to Storage Diseases and Back: A Personal Reminiscence -- Lysosomal Biogenesis and Disease -- The Concept of Treatment in Lysosomal Storage Diseases -- Complex Lipid Catabolism -- Retroviral Vectors for Gene Therapy -- Adenovirus in Gene Therapy -- Setting Back the Clock: Adenoviral-Mediated Gene Therapy for Lysosomal Storage Disorders -- Adeno-Associated Viral-Mediated Gene Therapy of Lysosomal Storage Disorders -- Herpes Simplex Virus Vectors for Gene Therapy of Lysosomal Storage Disorders -- Gene Therapy of Lysosomal Storage Disorders by Lentiviral Vectors -- Substrate Reduction Therapy -- Newborn Screening for Lysosomal Storage Disorders -- Genetic Counseling for Lysosomal Storage Diseases -- Neural Stem Cell Therapy in Lysosomal Storage Disorders -- The GM1 Gangliosidoses -- The GM2 Gangliosidoses -- Acid Sphingomyelinase-Deficient Niemann–Pick Disease -- Krabbe Disease (Globoid Cell Leukodystrophy) -- Metachromatic Leukodystrophy -- Fabry Disease -- Gaucher Disease: Review and Perspectives on Treatment -- Therapeutic Goals in the Treatment of Gaucher Disease -- The Neuronal Ceroid Lipofuscinoses: Clinical Features and Molecular Basis of Disease -- Mucopolysaccharidosis I -- Mucopolysaccharidosis II (Hunter Syndrome) -- Sanfilippo Syndrome: Clinical Genetic Diagnosis and Therapies -- Mucopolysaccharidosis IV (Morquio Syndrome) -- Mucopolysaccharidosis Type VI (Maroteaux–Lamy Syndrome) -- Mucopolysaccharidosis Type VII (Sly Disease): Clinical, Genetic Diagnosis and Therapies -- Pompe Disease-Glycogenosis Type II: Acid Maltase Deficiency -- Lysosomal Free Sialic Acid Storage Disorders: Salla Disease and ISSD -- Cystinosis -- I-Cell Disease.
520			_aLysosomal Biology and Storage Disorders John A. Barranger and Mario A. Cabrera-Salazar The knowledge of lysosomal biology and the consequences of its dysfunction have increased dramatically in the past 60 years. Research of these disorders has moved from diseases with unknown etiology to disorders with clear and defined pathophysiology and some of them have benefited from the development of disease specific therapeutics. Lysosomal Biology and Storage Disorders describes the nature of the diseases, the historical evolution of the field and future perspectives for the treatment of these clinical entities. Organized as a textbook, Lysosomal Biology and Storage Disorders describes the nature of lysosomal dysfunction, the synthesis and targeting of lysosomal enzymes and the implications of the targeting mechanisms for the development of new therapies. Disease specific chapters provide thorough reviews of the clinical features of lysosomal storage disorders, their molecular basis and the commercial or experimental therapeutic approaches sought in this area. Lysosomal Biology and Storage Disorders will be attract to all researchers in biochemical and molecular genetics, enzyme therapy, gene transfer, and others concerned with the models of genetic disease. This book is dedicated to patients affected by Lysosomal Storage Disorders, and especially to the National Gaucher Foundation (USA) and the Colombian Association of Patients with Lysosomal Storage Diseases (ACOPEL for its Spanish Acronym). Both organizations will share in the sales of this book. About the Editors: John A. Barranger, M.D., Ph.D. is a Professor in the departments of human genetics, molecular genetics and biochemistry, and pediatrics at the University of Pittsburgh School of Medicine. He has also served as director of the Human Gene Therapy Applications Laboratory, the Center for the Study and Treatment of Jewish Genetic Diseases, and the Comprehensive Gaucher Disease Treatment Center in this institution Mario A. Cabrera-Salazar, MD is a Staff Scientist at Genzyme Corporation in Framingham, MA. He is involved in the development of enzymatic and gene therapies for lysosomal storage disorders and for neurodegenerative diseases in the department of Genetic Disease Science.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aCabrera-Salazar, Mario A. _eautor _9305369
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9780387709086
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-0-387-70909-3 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c280446 _d280446